Inactive Instrument

Company Sigyn Therapeutics, Inc. Other OTC

Equities

SIGY

US82674U1060

Business Summary

Sigyn Therapeutics, Inc. is a development-stage company. The Company is focused on creating therapeutic solutions that address unmet needs in global health. The Company's product candidate, Sigyn Therapy, is a broad-spectrum blood purification technology designed to treat pathogen-associated inflammatory disorders. Its treatment indications include endotoxemia and inflammation in end-stage renal disease (dialysis) patients, sepsis (a cause of hospital deaths), community-acquired pneumonia (a cause of death among infectious diseases), and emerging pandemic threats. Sigyn Therapy is a single-use disposable device that is deployable on the global infrastructure of hemodialysis and continuous renal replacement therapy (CRRT) machines. The Company's development pipeline includes a cancer treatment system comprised of ChemoPrep to enhance the tumor site delivery of chemotherapy, and ChemoPure to reduce treatment toxicity and inhibit the spread of cancer metastasis.

Managers

Managers TitleAgeSince
Founder 71 19-10-18
Chief Executive Officer 62 19-10-18
Director of Finance/CFO 67 Dec. 11
Chief Operating Officer - 21-04-30
Chief Tech/Sci/R&D Officer - 21-01-25
Chief Tech/Sci/R&D Officer - 23-04-10

Members of the board

Members of the board TitleAgeSince
Chief Executive Officer 62 19-10-18
Director/Board Member 69 22-10-09
Director/Board Member 50 22-10-09
Founder 71 19-10-18
Director/Board Member 48 22-10-09

Shareholders

NameEquities%Valuation
320,500 26.25 % 2 M $
256,400 21.00 % 1 M $
Osher Capital, Inc.
6.246 %
76,266 6.246 % 419 463 $
Brio Capital Management LLC
0.1757 %
2,145 0.1757 % 11 798 $

Company contact information

Sigyn Therapeutics, Inc.

2468 Historic Decatur Road Suite 140

92106, San Diego

+

http://www.sigyntherapeutics.com
address Sigyn Therapeutics, Inc.(SIGY)

Sector

This company's sector is not yet available
  1. Stock Market
  2. Equities
  3. SIGY Stock
  4. SIGY Stock
  5. Company Sigyn Therapeutics, Inc.